Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Detection of cancer DNA in plasma of patients with early-stage breast cancer.

Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, Zabransky DJ, Wong HY, Valda Toro P, Cidado J, Blair BG, Chu D, Burns T, Higgins MJ, Stearns V, Jacobs L, Habibi M, Lange J, Hurley PJ, Lauring J, VanDenBerg DA, Kessler J, Jeter S, Samuels ML, Maar D, Cope L, Cimino-Mathews A, Argani P, Wolff AC, Park BH.

Clin Cancer Res. 2014 May 15;20(10):2643-50. doi: 10.1158/1078-0432.CCR-13-2933. Epub 2014 Feb 6.

2.

PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA.

Kim ST, Lira M, Deng S, Lee S, Park YS, Lim HY, Kang WK, Mao M, Heo JS, Kwon W, Jang KT, Lee J, Park JO.

Oncotarget. 2015 Nov 24;6(37):40026-35. doi: 10.18632/oncotarget.5432.

3.

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

Chu D, Paoletti C, Gersch C, VanDenBerg DA, Zabransky DJ, Cochran RL, Wong HY, Toro PV, Cidado J, Croessmann S, Erlanger B, Cravero K, Kyker-Snowman K, Button B, Parsons HA, Dalton WB, Gillani R, Medford A, Aung K, Tokudome N, Chinnaiyan AM, Schott A, Robinson D, Jacks KS, Lauring J, Hurley PJ, Hayes DF, Rae JM, Park BH.

Clin Cancer Res. 2016 Feb 15;22(4):993-9. doi: 10.1158/1078-0432.CCR-15-0943. Epub 2015 Aug 10.

4.

A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.

Jelovac D, Beaver JA, Balukrishna S, Wong HY, Toro PV, Cimino-Mathews A, Argani P, Stearns V, Jacobs L, VanDenBerg D, Kessler J, Jeter S, Park BH, Wolff AC.

Hum Pathol. 2014 Apr;45(4):880-3. doi: 10.1016/j.humpath.2013.10.016. Epub 2013 Oct 31.

5.

PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.

Oshiro C, Kagara N, Naoi Y, Shimoda M, Shimomura A, Maruyama N, Shimazu K, Kim SJ, Noguchi S.

Breast Cancer Res Treat. 2015 Apr;150(2):299-307. doi: 10.1007/s10549-015-3322-6. Epub 2015 Mar 4.

PMID:
25736040
6.

Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.

Ang D, O'Gara R, Schilling A, Beadling C, Warrick A, Troxell ML, Corless CL.

J Mol Diagn. 2013 May;15(3):312-8. doi: 10.1016/j.jmoldx.2012.12.005. Epub 2013 Mar 27.

PMID:
23541593
7.

Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.

Dirican E, Kaya Z, Gullu G, Peker I, Ozmen T, Gulluoglu BM, Kaya H, Ozer A, Akkiprik M.

Asian Pac J Cancer Prev. 2014;15(21):9327-33.

8.

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.

Kim ST, Lee WS, Lanman RB, Mortimer S, Zill OA, Kim KM, Jang KT, Kim SH, Park SH, Park JO, Park YS, Lim HY, Eltoukhy H, Kang WK, Lee WY, Kim HC, Park K, Lee J, Talasaz A.

Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465.

9.

PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.

Markou A, Farkona S, Schiza C, Efstathiou T, Kounelis S, Malamos N, Georgoulias V, Lianidou E.

Clin Cancer Res. 2014 Nov 15;20(22):5823-34. doi: 10.1158/1078-0432.CCR-14-0149.

10.

Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.

Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Fetting J, Emens L, Riley C, Stearns V, Diehl F, Angenendt P, Huang P, Cope L, Argani P, Murphy KM, Bachman KE, Greshock J, Wolff AC, Park BH.

Clin Cancer Res. 2012 Jun 15;18(12):3462-9. doi: 10.1158/1078-0432.CCR-11-2696. Epub 2012 Mar 15.

11.

High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.

Ney JT, Froehner S, Roesler A, Buettner R, Merkelbach-Bruse S.

Arch Pathol Lab Med. 2012 Sep;136(9):983-92. doi: 10.5858/arpa.2011-0176-OA.

PMID:
22938585
12.

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.

Papaxoinis G, Kotoula V, Alexopoulou Z, Kalogeras KT, Zagouri F, Timotheadou E, Gogas H, Pentheroudakis G, Christodoulou C, Koutras A, Bafaloukos D, Aravantinos G, Papakostas P, Charalambous E, Papadopoulou K, Varthalitis I, Efstratiou I, Zaramboukas T, Patsea H, Scopa CD, Skondra M, Kosmidis P, Pectasides D, Fountzilas G.

PLoS One. 2015 Oct 9;10(10):e0140293. doi: 10.1371/journal.pone.0140293. eCollection 2015.

13.

Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.

Qiu W, Tong GX, Manolidis S, Close LG, Assaad AM, Su GH.

Int J Cancer. 2008 Mar 1;122(5):1189-94.

14.

Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, Omoto Y, Iwase H.

Cancer Sci. 2015 Nov;106(11):1582-9. doi: 10.1111/cas.12813. Epub 2015 Oct 30.

15.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E.

Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.

PMID:
26184520
16.

Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.

Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y.

Oncologist. 2016 Feb;21(2):156-64. doi: 10.1634/theoncologist.2015-0288. Epub 2016 Jan 14.

17.

Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.

Guttery DS, Page K, Hills A, Woodley L, Marchese SD, Rghebi B, Hastings RK, Luo J, Pringle JH, Stebbing J, Coombes RC, Ali S, Shaw JA.

Clin Chem. 2015 Jul;61(7):974-82. doi: 10.1373/clinchem.2015.238717. Epub 2015 May 15.

18.

PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.

Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A, Pusztai L.

Breast Cancer Res. 2008;10(2):R27. doi: 10.1186/bcr1984. Epub 2008 Mar 27.

19.

Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.

Ahmad F, Badwe A, Verma G, Bhatia S, Das BR.

Med Oncol. 2016 Jul;33(7):74. doi: 10.1007/s12032-016-0788-y. Epub 2016 Jun 9.

PMID:
27282497
20.

PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.

Mangone FR, Bobrovnitchaia IG, Salaorni S, Manuli E, Nagai MA.

Clinics (Sao Paulo). 2012 Nov;67(11):1285-90.

Supplemental Content

Support Center